Literature DB >> 8257868

The management of subacute (DeQuervain's) thyroiditis.

R Volpé1.   

Abstract

Subacute (DeQuervain's) thyroiditis is a transient inflammatory thyroid disease usually associated with pain and tenderness of the gland, as well as generalized somatic symptoms, which can cause great discomfort or even complete prostration for weeks or months if left untreated. It is almost certainly the result of a viral infection. There is no definitive therapy for painful subacute thyroiditis, but there is effective treatment that will ameliorate the symptoms and allow the disease to run its spontaneous course in an asymptomatic fashion. Salicylates and nonsteroidal antiinflammatory drugs can be used in patients with mild or moderate forms of the disorder. In more severe forms of the condition, corticosteroids in suitable pharmacological dosage will generally cause a rapid relief of symptoms within 24-48 h. Prednisone may be initiated in dosages of 40 mg daily, with a gradual reduction in dosage thereafter over several weeks. Recurrences do appear in a small percentage of patients, necessitating restoration of a higher dose once again. Repeat exacerbations are uncommon. Other less common forms of treatment include triiodothyronine or thyroxine, generally to prevent repeated exacerbations. Irradiation is no longer employed. Thyroidectomy should be considered only in that very small minority of patients who have repeated relapses despite appropriate treatment. During the period of transient hypothyroidism, thyroxine may be provided but can usually be discontinued subsequently. General recovery is almost the universal rule and only less than 1% become permanently hypothyroid.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8257868     DOI: 10.1089/thy.1993.3.253

Source DB:  PubMed          Journal:  Thyroid        ISSN: 1050-7256            Impact factor:   6.568


  20 in total

1.  Diagnosis and Management of Infectious Thyroiditis.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  2000-04       Impact factor: 3.725

2.  de Quervain thyroiditis in a young boy following hand-foot-mouth disease.

Authors:  Pontipa Engkakul; Pat Mahachoklertwattana; Preamrudee Poomthavorn
Journal:  Eur J Pediatr       Date:  2010-10-01       Impact factor: 3.183

Review 3.  Eponym : de Quervain thyroiditis.

Authors:  Pontipa Engkakul; Pat Mahachoklertwattana; Preamrudee Poomthavorn
Journal:  Eur J Pediatr       Date:  2010-10-01       Impact factor: 3.183

4.  Subacute thyroiditis: clinical characteristics and treatment outcome in fifty-six consecutive patients diagnosed between 1999 and 2005.

Authors:  C A Benbassat; D Olchovsky; G Tsvetov; I Shimon
Journal:  J Endocrinol Invest       Date:  2007-09       Impact factor: 4.256

Review 5.  [Inflammatory diseases of the thyroid gland. Epidemiology, symptoms and morphology].

Authors:  S-Y Sheu; K W Schmid
Journal:  Pathologe       Date:  2003-06-19       Impact factor: 1.011

6.  Comparison of the therapeutic effects of prednisolone and nonsteroidal anti-inflammatory drugs in patients with subacute thyroiditis.

Authors:  Junko Sato; Toyoyoshi Uchida; Koji Komiya; Hiromasa Goto; Kageumi Takeno; Ruriko Suzuki; Akira Honda; Miwa Himuro; Hirotaka Watada
Journal:  Endocrine       Date:  2016-09-29       Impact factor: 3.633

Review 7.  [Endocrine disease symptoms].

Authors:  M Reincke
Journal:  Internist (Berl)       Date:  2013-10       Impact factor: 0.743

8.  Demographic and clinical features of patients with subacute thyroiditis: results of 169 patients from a single university center in Turkey.

Authors:  N Erdem; M Erdogan; M Ozbek; M Karadeniz; S Cetinkalp; A Gokhan Ozgen; F Saygili; C Yilmaz; M Tuzun; T Kabalak
Journal:  J Endocrinol Invest       Date:  2007 Jul-Aug       Impact factor: 4.256

9.  Initial treatment combined with Prunella vulgaris reduced prednisolone consumption for patients with subacute thyroiditis.

Authors:  Fuqiang Li; Yijun Wu; Liang Chen; Liang Hu; Xiaosun Liu
Journal:  Ann Transl Med       Date:  2019-02

10.  Subacute thyroiditis in an immunosuppressed patient.

Authors:  K Obuobie; A Al-Sabah; J H Lazarus
Journal:  J Endocrinol Invest       Date:  2002-02       Impact factor: 5.467

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.